You are here

First Treatment for Adult Chronic Rhinosinusitis With Nasal Polyps

Dupilumab Also Reduces Need for Polyp Surgery and Steroids

The FDA has approved dupilumab (Dupixent, Regeneron Pharmaceuticals and Sanofi) for adults with nasal polyps accompanied by prolonged inflammation of the sinuses and nasal cavity. It is the first treatment to be approved for inadequately controlled chronic rhinosinusitis with nasal polyps, which can lead to loss of smell.

The safety and efficacy of dupilumab were established in two studies involving 724 adults with chronic rhinosinusitis with nasal polyps who were symptomatic with use of intranasal corticosteroids. Patients who received dupilumab had statistically significant reductions in nasal polyp size and nasal congestion compared to patients receiving placebo. Dupilumab patients also reported an improved ability to smell and needed less nasal polyp surgery and fewer oral steroids.

Serious allergic reactions and eye problems can occur with dupilumab, including conjunctivitis and keratitis. The most commonly reported side effects were injection-site reactions and eye/eyelid inflammation, which included redness, swelling, and itching. Also, live vaccines should be avoided for patients taking dupilumab. 

Dupilumab was originally approved in 2017 for adult patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical therapies or when such therapies are inadvisable. In 2018, the drug was approved as add-on maintenance treatment for patients aged 12 and older with moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma. It was also approved in March 2019 for adolescent patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical therapies.

Source: FDA, June 26, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress